clinical trial · NCT01900054
A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis
Perennial Allergic RhinitisBepotastine besilate
brief summary
The objective of this study is to evaluate the long-term safety and efficacy of TAU-284 (Bepotastine besilate) in pediatric patients with perennial allergic rhinitis for 12 weeks administration.
started
Jun 1, 2013
primary completion
Nov 1, 2013
completion
Nov 1, 2013
last updated
Jan 7, 2026
detailed description
This is a multicenter,open-label, single-arm, uncontrolled study to evaluate the safety and efficacy of TAU-284 (20 mg/day) in pediatric patients with perennial allergic rhinitis for 12 weeks administration.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol